Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Vbc106

Preclinical

VVelaVigo Bio Inc

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Participants With Advanced Solid Tumor MalignanciesNot yet recruiting

Participants With Advanced Solid Tumor MalignanciesPreclinical

Not yet recruiting

Timeline

Expected Milestones

Q4 2028

PreclinicalNot yet recruiting

Participants With Advanced Solid Tumor Malignancies

NCT07686068

Clinical

Trials by Indication[1]

Participants With Advanced Solid Tumor Malignancies1 trial

Phase 1/2a Open-Label Clinical Trial Evaluating VBC106, an FRα- and MSLN-Directed Bispecific Antibody Drug Conjugate, in Participants With Advanced Malignant Solid Tumors

Not yet recruiting·VVelaVigo Bio Inc·Preclinical·NCT07686068·260 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Vbc106. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Vbc106. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — VelaVigo Bio Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: VVelaVigo Bio Inc

Related News